Cytokinetics INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
CYTK
Cytokinetics INCForm 4: Cytokinetics CEO Sells Shares
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on October 12, 2026 for $62.88 per share.
NASDAQ
CYTK
Cytokinetics INCFady Ibraham Malik, EVP Research & Development of Cytokinetics Inc, sold 3,500 shares of common stock on October 6, 2026 for $61.38 per share.
NASDAQ
CYTK
Cytokinetics INCForm 4: Cytokinetics CEO Sells Shares
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on September 28, 2026 for $65.46 per share.
NASDAQ
CYTK
Cytokinetics INCFady Ibraham Malik, EVP Research & Development of Cytokinetics Inc, sold 3,500 shares of common stock on September 22, 2026 for $68.29 per share.
NASDAQ
CYTK
Cytokinetics INCRobert E Landry, a Director of Cytokinetics Inc, sold 1,000 shares of common stock on September 15, 2026 for $72.13 per share.
NASDAQ
CYTK
Cytokinetics INCForm 4: Cytokinetics CEO Sells Shares
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 105,426 shares of common stock on September 14, 2026.
NASDAQ
CYTK
Cytokinetics INCRobert E Landry, a Director of Cytokinetics Inc, sold 1,000 shares of common stock on September 11, 2026 for $74.66 per share.
NASDAQ
CYTK
Cytokinetics INCFady Ibraham Malik, EVP Research & Development of Cytokinetics Inc, sold 3,500 shares of common stock on September 8, 2026 for $75.46 per share.
NASDAQ
CYTK
Cytokinetics INCB Lynne Parshall, a Director of Cytokinetics Inc, sold 5,000 shares of common stock on September 1, 2026 for $71.48 per share.
NASDAQ
CYTK
Cytokinetics INCAndrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 10,000 shares of common stock on August 31, 2026 for $70.24 per share.
NASDAQ
CYTK
Cytokinetics INCForm 4: Cytokinetics CEO Sells Shares
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on August 31, 2026 for $70.24 per share.
NASDAQ
CYTK
Cytokinetics INCFady Ibraham Malik, EVP Research & Development of Cytokinetics Inc, sold 3,500 shares of common stock on August 18, 2026 for $75.82 per share.
NASDAQ
CYTK
Cytokinetics INCForm 4: Cytokinetics CEO Sells Shares
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on August 10, 2026 for $76.76 per share.
NASDAQ
CYTK
Cytokinetics INCAndrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 14,000 shares of common stock on July 30, 2026 for $79.88 per share.
NASDAQ
CYTK
Cytokinetics INCForm 4: Cytokinetics CEO Sells Shares
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on July 27, 2026 for $80.87 per share.
NASDAQ
CYTK
Cytokinetics INCFady Ibraham Malik, EVP Research & Development of Cytokinetics Inc, sold 3,500 shares of common stock on July 21, 2026 for $80.59 per share.
NASDAQ
CYTK
Cytokinetics INCNancy Wysenski, a Director of Cytokinetics Inc, received 75 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INCWendell Wierenga, a Director of Cytokinetics Inc, received 75 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INCEdward M. Kaye, a Director of Cytokinetics Inc, received 151 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INCJohn T Henderson, a Director of Cytokinetics Inc, received 272 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INCRobert Arthur Harrington, a Director of Cytokinetics Inc, received 151 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INCJames M Daly, a Director of Cytokinetics Inc, received 151 shares of common stock on July 15, 2026.
NASDAQ
CYTK
Cytokinetics INCForm 4: Cytokinetics CEO Sells Shares
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on July 13, 2026 for $82.02 per share.
NASDAQ
CYTK
Cytokinetics INCCytokinetics EVP of Research & Development, Fady Ibraham Malik, acquired 3,500 shares of common stock and disposed of 3,500 stock options.
NASDAQ
CYTK
Cytokinetics INCCytokinetics CEO Robert I. Blum reported a sale of 7,500 shares of common stock on July 1, 2026, for $84.92 per share.
NASDAQ
CYTK
Cytokinetics INCCytokinetics EVP Andrew Callos engaged in a series of transactions, selling 15,000 shares of common stock and acquiring 15,000 stock options.
NASDAQ
CYTK
Cytokinetics INCCytokinetics' CFO, Lee Sung, acquired 1,112 shares of common stock and exercised a stock option for the same amount on July 1, 2026, as reported in a Form 4 filing.
NASDAQ
CYTK
Cytokinetics INCCytokinetics EVP, Chief Financial Officer Lee Sung reported transactions involving the acquisition and disposition of common stock and stock options on June 24, 2026.
NASDAQ
CYTK
Cytokinetics INCCytokinetics' CFO, Lee Sung, has acquired a significant number of company shares through various stock option exercises and purchases.
NASDAQ
CYTK
Cytokinetics INCCytokinetics Inc. reports that President & CEO Robert I. Blum acquired 7,500 shares of common stock on June 15, 2026, for $70.46 per share.